Melanoma Diagnosis in the Mihm Era—And Beyond
ABSTRACT During the illustrious career of Martin C. Mihm Jr., MD, the diagnosis of melanoma underwent significant changes, to which he made many contributions. In early descriptions, melanomas were fungating tumor masses that were obviously malignant, and highly lethal. In seminal work by Dr. Mihm and his mentor, Wallace H.
David E. Elder
wiley +1 more source
Atypical Ductal Hyperplasia Diagnosis by Directional Vacuum-Assisted Stereotactic Biopsy of Breast Microcalcifications: Considerations for Surgical Excision [PDF]
Nour Sneige +6 more
openalex +1 more source
Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ
G. Tozbikian +8 more
semanticscholar +1 more source
Treatment‐related changes in the prostate: past, present and future therapies
Radiation therapy alters tumour morphology and immunoprofile in prostate cancer. Residual carcinoma shows distorted glandular architecture on H&E and loss of basal markers with preserved AMACR expression by immunohistochemistry, aiding in the recognition of treatment effect in prostate biopsies.
Katrina Collins, Liang Cheng
wiley +1 more source
Oncological and reproductive outcomes of endometrial atypical hyperplasia and endometrial cancer patients undergoing conservative therapy with hysteroscopic resection: A systematic review and meta-analysis. [PDF]
Zhao S +9 more
europepmc +1 more source
[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study]. [PDF]
Yuanyuan Wang +6 more
openalex +1 more source
Induction of Atypical Ductal Hyperplasia in Mouse Mammary Gland Organ Culture [PDF]
Rajendra G. Mehta +8 more
openalex +1 more source
Value of breast MRI for patients with a biopsy showing atypical ductal hyperplasia (ADH)
K. Tsuchiya +6 more
semanticscholar +1 more source
Molecular pathology of testicular germ cell tumours: an update for practicing pathologists
Molecular testing for isochromosome 12p is usually only necessary in difficult cases that encompass metastases or recurrent diseases including somatic‐type malignancies. So far, no breaking progress has been made in the field of targeted therapy as TGCTs only rarely show targetable molecular alterations.
Alexander Fichtner +3 more
wiley +1 more source

